Toll Free: 1-888-928-9744

Paralysis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 45 | Publisher: Global Markets Direct
Industry: Medical Devices | Report Format: Electronic (PDF)

Paralysis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Paralysis - Pipeline Review, H1 2015’, provides an overview of the Paralysis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paralysis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paralysis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Paralysis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Paralysis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Paralysis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Paralysis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Paralysis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Paralysis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Paralysis Overview 6
Therapeutics Development 7
Pipeline Products for Paralysis - Overview 7
Pipeline Products for Paralysis - Comparative Analysis 8
Paralysis - Therapeutics under Development by Companies 9
Paralysis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Paralysis - Products under Development by Companies 13
Paralysis - Companies Involved in Therapeutics Development 14
Asahi Kasei Pharma Corp. 14
Immunome Inc. 15
Marathon Pharmaceuticals, LLC 16
Neuralstem, Inc. 17
Paralysis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BNZ-1321 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
elcatonin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
flunarizine hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody Conjugates for Paralysis - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NSI-566 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
REM-1086 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Paralysis - Recent Pipeline Updates 35
Paralysis - Dormant Projects 42
Paralysis - Discontinued Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables

Number of Products under Development for Paralysis, H1 2015 7
Number of Products under Development for Paralysis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Comparative Analysis by Unknown Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Paralysis - Pipeline by Asahi Kasei Pharma Corp., H1 2015 14
Paralysis - Pipeline by Immunome Inc., H1 2015 15
Paralysis - Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 16
Paralysis - Pipeline by Neuralstem, Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Paralysis Therapeutics - Recent Pipeline Updates, H1 2015 35
Paralysis - Dormant Projects, H1 2015 42
Paralysis - Discontinued Products, H1 2015 43 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify